HRS9531 injection
Sponsors
Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions
Diabetes MellitusDiabetes Mellitus, Type 2ObesityOverweight or ObesityOverweight/ObesityType 2 DiabetesWeight LossWeight Management
Phase 1
Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects
CompletedNCT06654960
Start: 2024-11-05End: 2024-12-26Updated: 2025-01-07
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects
CompletedNCT06762600
Start: 2025-01-16End: 2026-03-12Updated: 2026-04-30
The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution
CompletedNCT06792955
Start: 2025-02-11End: 2025-06-06Updated: 2025-06-12
A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function
Not yet recruitingNCT07540754
Start: 2026-05-01End: 2027-02-01Target: 24Updated: 2026-04-20
Phase 2
Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
CompletedNCT05881837
Start: 2023-06-13End: 2024-10-13Updated: 2025-04-30
Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
CompletedNCT05966272
Start: 2023-08-12End: 2024-09-24Updated: 2025-05-07
Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects
CompletedNCT06054698
Start: 2023-10-16End: 2024-09-09Updated: 2026-05-22
A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea
Not yet recruitingNCT06565871
Start: 2024-08-31End: 2025-12-31Target: 108Updated: 2024-08-22
Phase 3
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
CompletedNCT06396429
Start: 2024-05-13End: 2025-07-07Updated: 2025-07-11
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Active, not recruitingNCT06649344
Start: 2024-10-31End: 2026-09-30Updated: 2025-06-12
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
Active, not recruitingNCT06650007
Start: 2024-11-08End: 2026-07-31Updated: 2025-06-12
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
Active, not recruitingNCT07285902
Start: 2025-12-25End: 2027-03-01Updated: 2026-02-27